Pharmaceutical News

RSS

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

U.S. Court of Appeals rules against Eli Lily's claims in Gemzar patent lawsuit

Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.

29 Jul 2010

Online pharmacy services Pharmahelper.com, QC Supply, and Kerr Drug earn NABP e-Advertiser Approval

The National Association of Boards of Pharmacy® (NABP®) has named Pharmahelper.com, QC Supply, and Kerr Drug as the first online pharmacy services to be approved through the Association's new e-Advertiser Approval(CM) Program now required by Google, Microsoft, and Yahoo!. As such, these entities offer reliable and trustworthy resources for patients seeking to purchase medications safely online.

29 Jul 2010

AHF accuses Bristol-Myers Squibb of lying about cooperation with HIV/AIDS community

Today AIDS Healthcare Foundation (AHF) responded to a statement placed by drug giant Bristol-Myers Squibb (BMS) on its website defending its record on AIDS drug pricing and accessibility.

29 Jul 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has upheld a prior ruling by the U.S. District Court for the Eastern District of Michigan that Gemzar's method-of-use patent is invalid.

29 Jul 2010

Partnership for Safe Medicines to convene counterfeit drug conference

The Partnership for Safe Medicines (PSM), a group of nonprofit organizations and individuals dedicated to protecting consumers from counterfeit drugs, today announced that it will convene leaders from academia, government and industry in an inaugural conference to be held October 8th at the National Press Club in Washington, D.C.

29 Jul 2010

Scientists develop new version of medication to relieve severe forms of pain

Scientists have developed a new version of a medication, first isolated from the saliva of sea snails, that could be taken in pill form to relieve the most severe forms of pain as effectively as morphine but without risking addiction. An article on the topic appears in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

29 Jul 2010

Oxford Finance leads $30 million credit facility provided to Cadence for launch of OFIRMEV

Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, today announced that it was the lead lender for a $30 million credit facility provided to Cadence Pharmaceuticals. Silicon Valley Bank and GE Financial Services, Inc. also participated in the loan agreement. This infusion of capital will support the company's potential launch of their investigational product candidate, OFIRMEV™, an intravenous formulation of acetaminophen that is currently marketed in Europe for the treatment of acute pain and fever.

29 Jul 2010

Advanced Protein Systems is now APS BioGroup

APS BioGroup, formerly Advanced Protein Systems, the world's largest producer of colostrum products, announces its new company name and expanded focus to include advancements in private label contract manufacturing for health supplements and the introduction of Immulox®, an immune support product and supplement ingredient derived from colostrum.

29 Jul 2010

FRC Action, pro-life groups urge FDA to reject approval of Ella

Today FRC Action joined 19 pro-life groups in a letter sent to Food and Drug Administration Commissioner Margaret Hamburg requesting that Ella, a drug under consideration for FDA approval that can cause abortions but is misleadingly labeled as an "emergency contraceptive," not be approved.

29 Jul 2010

Sanofi-aventis U.S joins Dispensary of Hope's Continued Access Program

The Dispensary of Hope is pleased to announce that sanofi-aventis U.S., the U.S. affiliate of sanofi-aventis, a leading global pharmaceutical company, has become the latest pharmaceutical company to participate in the Dispensary's Continued Access Program, which provides uninsured patients with access to medicines that they otherwise couldn't afford.

29 Jul 2010

New test to predict suitable treatment for chronic myeloid leukemia patients

Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).

29 Jul 2010

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

AstraZeneca today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes.

29 Jul 2010

Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

29 Jul 2010

FDA approves Cuvposa Oral Solution for chronic severe drooling in children

The U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.

29 Jul 2010

Bioniche, Synerx announce FDA approval and launch of Isosulfan Blue Injection 1%

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.

29 Jul 2010

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.

29 Jul 2010

Rite Aid agrees to pay $1 million to settle medical privacy questions

The Wall Street Journal: "Rite Aid Corp. agreed to pay $1 million to settle potential violations of government privacy rules after regulators said it failed to protect customers' and employees' financial and medical information. The drug-store chain's agreement with the Federal Trade Commission requires the company to establish an information-security program and obtain a third-party audit of its compliance to that effect every two years for the next 20 years."

29 Jul 2010

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010. For the second quarter, AMAG reported total revenue of $18.8 million, including $16.0 million of Feraheme® (ferumoxytol) Injection for intravenous (IV) use net product revenues.

29 Jul 2010

Pharmaceutical News

AVEO second-quarter total revenues increase to $15.6 million

U.S. Court of Appeals rules against Eli Lily's claims in Gemzar patent lawsuit

Online pharmacy services Pharmahelper.com, QC Supply, and Kerr Drug earn NABP e-Advertiser Approval

AHF accuses Bristol-Myers Squibb of lying about cooperation with HIV/AIDS community

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Partnership for Safe Medicines to convene counterfeit drug conference

Scientists develop new version of medication to relieve severe forms of pain

Oxford Finance leads $30 million credit facility provided to Cadence for launch of OFIRMEV

Advanced Protein Systems is now APS BioGroup

FRC Action, pro-life groups urge FDA to reject approval of Ella

Sanofi-aventis U.S joins Dispensary of Hope's Continued Access Program

New test to predict suitable treatment for chronic myeloid leukemia patients

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial

FDA approves Cuvposa Oral Solution for chronic severe drooling in children

Bioniche, Synerx announce FDA approval and launch of Isosulfan Blue Injection 1%

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Rite Aid agrees to pay $1 million to settle medical privacy questions

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News